Dms53

Manufactured by American Type Culture Collection

Sourced in United States

The DMS53 is a laboratory equipment designed for precise liquid handling and dispensing. It features programmable and accurate liquid aspiration and dispensing capabilities, with options for multiple sample aspirations and dispensing. The core function of the DMS53 is to provide reliable and consistent liquid handling for a variety of laboratory applications.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

DMS53 cells (2 citations)

22 protocols using dms53

Mesothelioma and Lung Cancer Cell Line Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mesothelioma (MERO-14, MERO-41, MERO-82, NO36, ONE58, MSTO-211H, NCI-H226, NCI-H2052) and lung cancer (NCI-H1703, -H211, -H526, -H522, -H520, -H460, -H358, -H1395, -H2122, -H2023, -H1651, A549, SW1573, DMS-114, DMS-53) cell lines were obtained from ATCC (Manassas, VA), DSMZ (Braunschweig, Germany), or Sigma-Aldrich (St. Louis, MO). Cells were cultured in the appropriate culture medium supplemented with 10% fetal bovine serum (FBS) at 37°C in humidified incubators under 5% CO₂. Heparin sodium salt and growth factors were purchased from Sigma-Aldrich. GSK3052230 is formulated in 0.94 mg/mL sodium phosphate monobasic, 1.9 mg/mL sodium phosphate dibasic, 8.8 mg/mL sodium chloride, 0.2 mg/mL polysorbate 80, pH 7.0 at a stock concentration of 12.8 mg/mL. NVP-BGJ398 was purchased from Selleck Chemicals (Houston, TX) and dissolved in DMSO at a stock concentration of 20 mM.

Blackwell C., Sherk C., Fricko M., Ganji G., Barnette M., Hoang B., Tunstead J., Skedzielewski T., Alsaid H., Jucker B.M., Minthorn E., Kumar R, & DeYoung M.P. (2016). Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. Oncotarget, 7(26), 39861-39871.

+ Open protocol

+ Expand

Cell Line Maintenance and Validation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human SCLC cell line SBC3 was gifted by Dr. Takashi Kijima (Osaka University, Japan), and SBC5 was obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan. BEAS-2B, DMS273, DMS53, NCI-H82, NCI-H526, NCI-H69 and Colo668 were originally obtained from ATCC (Rockville, MD, USA). All the cell lines were routinely maintained and cultured in standard culture conditions, in a CO₂ incubator at 37 °C, and regularly validated using STR profiling and checked for mycoplasma infections prior to experiments. For routine maintenance, SBC3, SBC5, NCI-H82, NCI-H69, NCI-H526, DMS273, DMS53, and Colo668 cells were cultured in RPMI-1640 medium supplemented with 1500 mg/L sodium bicarbonate, 10% fetal bovine serum (Sigma Cat#12303C), 1% penicillin/streptomycin cocktail solution (Invitrogen Cat#15,140–122), 1% sodium pyruvate (Invitrogen Cat#11,360,070), and 1% L-glutamine (Invitrogen Cat#25,030–081).

Khan P., Siddiqui J.A., Kshirsagar P.G., Venkata R.C., Maurya S.K., Mirzapoiazova T., Perumal N., Chaudhary S., Kanchan R.K., Fatima M., Khan M.A., Rehman A.U., Lakshmanan I., Mahapatra S., Talmon G.A., Kulkarni P., Ganti A.K., Jain M., Salgia R., Batra S.K, & Nasser M.W. (2023). MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Molecular Cancer, 22, 1.

+ Open protocol

+ Expand

Lung Cancer Cell Line Transfection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lung adenocarcinoma cell lines A549 and PC9, human large cell lung cancer cell line H460, human lung squamous cell carcinoma cell line H520, and human small cell lung cancer cell lines DMS53 and DMS114 were purchased from ATCC (Manassas, VA, USA). The lung adenocarcinoma cell line II18 was purchased from RIKEN Cell Bank (Riken, Tsukuba, Japan). These cells were cultured at 37°C with 5% CO₂ in RPMI-1640 medium (Wako, Japan) containing 10% fetal calf serum. The tumor cells were transfected with a CARD9 siRNA (Thermo Fisher Scientific, MA) or with Silencer^® Select Negative Control No. 1 siRNA (Thermo Fisher Scientific, MA), which had no effect on any gene expression.

Miwa N., Nagano T., Jimbo N., Dokuni R., Kiriu T., Mimura C., Yasuda Y., Katsurada M., Yamamoto M., Tachihara M., Tanaka Y., Kobayashi K., Itoh T., Maniwa Y, & Nishimura Y. (2020). Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma. OncoTargets and therapy, 13, 9005-9013.

+ Open protocol

+ Expand

Lurbinectedin Treatment on Lung Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following cell lines were obtained from the ATCC: A549 (lung adenocarcinoma; CCL‐185), DMS‐53 (small‐cell lung carcinoma; CRL‐2062), IMR‐90 (normal lung; CCL‐186), NCI‐H69 (small‐cell lung carcinoma; HTB‐119), NCI‐H82 (small‐cell lung carcinoma; HTB‐175), NCI‐H146 (small‐cell lung carcinoma; HTB‐173), NCI‐H460 (large cell lung carcinoma; HTB‐177), NCI‐H510A (small‐cell lung carcinoma; HTB‐184), NCI‐H526 (small‐cell lung carcinoma; CRL‐5811), and SHP‐77 (small‐cell lung carcinoma; CRL‐2195). The cells were authenticated and tested for mycoplasma contamination. All cell lines were cultured in the medium and conditions recommended by the supplier and supplemented with 10%FBS, 2 nmol/L l‐glutamine, and penicillin–streptomycin mix (Sigma). For lurbinectedin treatment, cells were seeded and grown to subconfluency before the addition of the drug to the culture medium after having optimized drug concentration (50 nM) and time of lurbinectedin treatment (4 h).

Costanzo F., Martínez Diez M., Santamaría Nuñez G., Díaz‐Hernandéz J.I., Genes Robles C.M., Díez Pérez J., Compe E., Ricci R., Li T., Coin F., Martínez Leal J.F., Garrido‐Martin E.M, & Egly J.M. (2022). Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells. EMBO Molecular Medicine, 14(4), e14841.

+ Open protocol

+ Expand

SCLC Cell Line Cultivation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human SCLC cell lines H446, DMS79, H524, H526, H82, H847, H841, H196, H211, H146, SHP77, H345, H2196, H1436, H865, H1522, H1341, H1105, H1048, H1092, H1876, H69, DMS53, and H2029 were obtained from ATCC (Manassas, VA, USA) or Sigma-Aldrich (St. Louis, MO, USA). The human patient-derived xenograft (PDX) cell line NJH29 was generously provided by Dr. Julien Sage (Stanford University, Stanford, CA, USA). For experimentation, cell lines were cultured in RPMI-1640 supplemented with 10% FBS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. Cells were maintained in a 37 °C humidified chamber with 5% CO₂. All cell lines used were passaged for less than 6 months and regularly tested for Mycoplasma contamination using a MycoAlert Plus Kit (Lonza).

Cargill K.R., Stewart C.A., Park E.M., Ramkumar K., Gay C.M., Cardnell R.J., Wang Q., Diao L., Shen L., Fan Y.H., Chan W.K., Lorenzi P.L., Oliver T.G., Wang J, & Byers L.A. (2021). Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer & Metabolism, 9, 33.

+ Open protocol

+ Expand

Transfection of Human SCLC Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human SCLC cell lines SHP-77 and DMS 53 (ATCC, USA) were used in this study. The cell culture medium was a mixture of 10% FBS and 90% RPMI-1640 medium. Under the conditions of 37 °C, 95% humidity and 5% CO_2, cells were cultivated to reach 80% confluence, followed by transient transfections. Cells were transfected with pcDNA3.1-LINC01116 expression vector, pcDNA3.1-STAT3 expression vecto or miR-93-5p mimic (Invitrogen) using lipofectamine 2000 (Sigma-Aldrich). NC and C experiments were also included.

Liu W., Liang F., Yang G, & Xian L. (2021). LncRNA LINC01116 sponges miR-93-5p to promote cell invasion and migration in small cell lung cancer. BMC Pulmonary Medicine, 21, 50.

+ Open protocol

+ Expand

SCLC Cell Lines and Tissue Arrays

Check if the same lab product or an alternative is used in the 5 most similar protocols

SCLC cell lines, DMS 53 and DMS 114, as well as primary bronchial/tracheal epithelial cells (PBTEC) were all purchased from the American Type Culture Collection (ATCC) and cultured as recommended by the manufacturer. All experiments were carried out using cells harvested at low (<20) passages. A compound library consisting of 756 natural products was purchased from Selleck Chemicals. The SCLC formalin‐fixed, paraffin‐embedded (FFPE) tissue arrays, which contained 80 cases (Cat. #LC818c), and normal lung tissue arrays, which contained 24 cases (Cat. #LCN241), were purchased from US Biomax.

Chen J., Barrett L., Lin Z., Kendrick S., Mu S., Dai L, & Qin Z. (2022). Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target. Journal of Cellular and Molecular Medicine, 26(9), 2557-2565.

+ Open protocol

+ Expand

Characterization of SCLC Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human SCLC cell lines (H146, H187, H128, H69, H209, DMS153, H526, DMS114, and DMS53) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cell line purity was authenticated by short tandem repeat (STR) profiling at the Winship Cancer Institute Genomics Laboratory. The authenticity was confirmed for all cell lines except H128. The STR pattern for H128 was not consistent with the published references but consistent with the profiles for NCI-H60 (ATCC CRL-5821) and NCI-N417 (ATCC CRL-5809). It is noteworthy that we did not have the NCI-H60 and NCI-N417 in our lab throughout the duration of this work. Cells were grown as suspension or partially attached monolayer culture in RPMI 1640 medium supplemented with 5–10% fetal bovine serum at 37°C under humidified condition of 5% CO₂ and 95% air.

Owonikoko T.K., Zhang G., Deng X., Rossi M.R., Switchenko J.M., Doho G.H., Chen Z., Kim S., Strychor S., Christner S.M., Beumer J., Li C., Yue P., Chen A., Sica G.L., Ramalingam S.S., Kowalski J., Khuri F.R, & Sun S.Y. (2014). Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Medicine, 3(6), 1579-1594.

+ Open protocol

+ Expand

Comprehensive Cancer Cell Line Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

A549, BT-20, BT-474, BT-549, CAMA-1, DMS-53, DU4475, HCC38, HCC70, HCC202, HCC1143, HCC1187, HCC1395, HCC1569, HCC1806, HCC1937, HCC1954, HCC2218, HCT-116, Hs578T, Jeko-1, MCF-7, MDA-MB-134-VI, MDA-MB-157, MDA-MB-175-VII, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-436, MDA-MB-453, MDA-MB-468, MiaPaCa2, SK-BR-3, NCI-H441, SK-MEL-28, T-47D, U2OS, and ZR-75-1 were obtained from the American Type Culture Collection (ATCC) and cultured according to vendor recommendations. EFM-19 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) and SNU-886 were from the Korean Cell Line Bank (KCLB).
Abemaciclib, palbociclib, ribociclib, PIM447, BYL719, LY2090314, everolimus, DYRK1Bi AZ cpd 33 [32 (link)], dinaciclib, GSK2334470, abemaciclib metabolites M2 and M20 [28 (link)], and additional CDK4/6i (see Figure 2C [33 ],) were synthesized by Lilly Research Laboratories. AZD1208 (S7104) and additional palbociclib (S1579, see Supplementary Figure 1A) were purchased from Selleck Chemicals.

Litchfield L.M., Boehnke K., Brahmachary M., Mur C., Bi C., Stephens J.R., Sauder J.M., Gutiérrez S.M., McNulty A.M., Ye X.S., Wu W., Lallena M.J., Gong X., Merzoug F.F., Jansen V.M, & Buchanan S.G. (2020). Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells. Oncotarget, 11(17), 1478-1492.

+ Open protocol

+ Expand

Cell Culture Protocols for Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

HCT-116 and DMS-53 cells were obtained from the ATCC (American Type Culture Collection, Manassas, VA). H1299 cells were kindly provided by the Lung SPORE cell line repository at H. Lee Moffitt Cancer Center & Research Institute. HCT-116/δOR cells were previously generated in our lab using pcDNA-δOR15 vector containing a truncated δOR lacking the final 15 C-terminal amino acids. ^{45 (link)} HCT-116 and HCT-116/δOR cells were cultured in DMEM/F-12 (1:1) media containing 365 mg/L L-Glutamine, 2.438 g/L Sodium Bicarbonate (Life Technologies, Gibco), 10% fetal bovine serum (Atlanta Biologicals), 100 units/mL penicillin, and 100 µg/mL streptomycin. H1299 cells were cultured in RPMI-1640 media containing 300 mg/L L-Glutamine (Life Technologies, Invitrogen), 10% fetal bovine serum (Atlanta Biologicals), 100 units/mL penicillin, and 100 µg/mL streptomycin. DMS-53 cells were cultured in RPMI-1640 media containing 300 mg/L L-Glutamine (Life Technologies, Invitrogen) and 10% fetal bovine serum (Atlanta Biologicals). The cells were incubated in 5% CO₂ at 37 °C. Throughout this study, the morphology and growth characteristics of these cells were monitored by microscopy.

Cohen A.S., Patek R., Enkemann S.A., Johnson J.O., Chen T., Toloza E., Vagner J, & Morse D.L. (2015). Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo. Bioconjugate chemistry, 27(2), 427-438.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!